局部半胱胺治疗肾性胱氨酸病的疗效
该前瞻性研究纳入32例肾性胱氨酸病患者,使用0.55%半胱胺滴眼液治疗角膜胱氨酸结晶沉积,平均随访4.1年。结果显示,有症状患者的畏光改善无临床意义,而角膜胱氨酸沉积在随访期间出现统计学显著加重。作者认为,局部0.55%半胱胺滴眼液对严重型肾性胱氨酸病患者的角膜胱氨酸沉积疗效可能有限。
要点
- 32例肾性胱氨酸病患者接受0.55%半胱胺滴眼液治疗,平均随访4.1年。
- 有症状患者的畏光改善无临床意义。
- 随访期间角膜胱氨酸沉积出现统计学显著加重。
核心结论
- 局部0.55%半胱胺滴眼液对严重型肾性胱氨酸病患者的角膜胱氨酸沉积可能疗效有限。
研究设计与样本
- 前瞻性纳入32例肾性胱氨酸病患者,接受局部0.55%半胱胺滴眼液治疗,治疗前、每月随访及末次随访时检查。
主要发现
- 畏光改善在有症状患者中无临床意义。
- 随访期间角膜胱氨酸沉积出现统计学显著加重。
关键数值与推荐
- 畏光分级:0级为无畏光,1级为强光下畏光,2级为室内光下畏光,3级为暗光下畏光。
- 角膜胱氨酸结晶分级:0级为无,1级为1-10个/mm2,2级为11-50个/mm2,3级为超过50个/mm2。
- 患者平均年龄8岁(范围8个月至19岁),平均随访4.1年(范围2-8年)。
- 共13例男性、19例女性患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study is to evaluate the efficacy of topical cysteamine 0.55% eye drops in the treatment of corneal cystine crystal deposits in patients with nephropathic cystinosis. METHODS: Thirty-two patients with nephropathic cystinosis were prospectively included in the study. Patients with corneal cystinosis were treated with topical cysteamine 0.55% eye drops. They were examined before treatment, on each monthly visit and after treatment at the last follow-up. Photophobia was classified as grade 0 (none) for no photophobia, grade 1 (mild) for photophobia in bright light, grade 2 (moderate) for photophobia in room light and grade 3 (severe) for photophobia in dim light. Corneal cystine crystals were graded as grade 0=none, grade 1=1-10 crystals/mm2, grade 2=11-50 crystals/mm2, grade 3=more than 50 crystals/mm2. The main outcome measure was evaluation of photophobia and resolution of corneal cystine crystals. RESULTS: There were 13 male and 19 female patients. The mean age was 8 years with an age range of 8 months to 19 years. The mean follow-up period was 4.1 years with a range of 2-8 years. Improvement of photophobia was not clinically significant in symptomatic patients. Patients displayed statistically significant worsening of corneal cystine deposits during the follow-up period. CONCLUSIONS: This study has shown that topical 0.55% cysteamine eye drops may have limited effects in decreasing the corneal cystine deposits in patients with severe forms of nephropathic cystinosis. TRIAL REGISTRATION NUMBER: NCT02766855, Results.
引用
- Al-Hemidan A, Shoughy SS, Kozak I, et al. Efficacy of topical cysteamine in nephropathic cystinosis. Br J Ophthalmol. 2017. PMID: 28057644. doi:10.1136/bjophthalmol-2016-309278
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。